Muhlebach M S, MacDonald S L, Button B, Hubbard J J, Turner M L, Boucher R C, Kilpatrick D C
Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.
Clin Exp Immunol. 2006 Aug;145(2):302-7. doi: 10.1111/j.1365-2249.2006.03151.x.
An association between mannan-binding lectin (MBL) status and severity of lung function impairment in cystic fibrosis (CF) has been found in several studies, but not in others. To explore the possible basis for discrepancies in the literature, we related both MBL and L-ficolin concentrations to lung function and examined the results in relation to the age of the patients. For patients under 15 years of age, those with MBL < 200 ng/ml had better lung function than those with MBL > 200 ng/ml [median forced expiratory volume in 1 s (FEV(1)), 99% versus 83%; P = 0.05]. For patients over 15 years of age, those with MBL < 200 ng/ml had poorer lung function than those with MBL > 200 ng/ml (median FEV(1), 44% versus 55%; P = 0.1). Also, for the over 15-year-olds, the proportion of patients with FEV(1) values below the median was greater in the MBL-insufficient subgroup (P < 0.04). In other words, relative deficiency of MBL appears to accelerate the age-related decline in lung function in CF patients. No corresponding relationships could be found between L-ficolin concentration and lung function. These findings and interpretation lend support to the potential value of MBL replacement therapy in a small minority of cystic fibrosis patients.
多项研究发现甘露聚糖结合凝集素(MBL)状态与囊性纤维化(CF)患者肺功能损害的严重程度之间存在关联,但其他一些研究却未发现此关联。为探究文献中存在差异的可能原因,我们将MBL和L-纤维胶凝蛋白的浓度与肺功能相关联,并根据患者年龄对结果进行了分析。对于15岁以下的患者,MBL<200 ng/ml的患者肺功能优于MBL>200 ng/ml的患者[第1秒用力呼气量(FEV(1))中位数,分别为99%和83%;P = 0.05]。对于15岁以上的患者,MBL<200 ng/ml的患者肺功能比MBL>200 ng/ml的患者差(FEV(1)中位数,分别为44%和55%;P = 0.1)。此外,对于15岁以上的患者,MBL不足亚组中FEV(1)值低于中位数的患者比例更高(P < 0.04)。换句话说,MBL相对缺乏似乎会加速CF患者肺功能与年龄相关的下降。在L-纤维胶凝蛋白浓度与肺功能之间未发现相应关系。这些发现及解释支持了MBL替代疗法在少数囊性纤维化患者中的潜在价值。